LMR Partners’s Aquestive Therapeutics AQST Stock Holding History

LMR Partners’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-200,000	Closed	-$1.29M	–	1450
2025 Q4	$1.29M	Buy	+200,000	New	+$1.25M	﹤0.01%	918

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LMR Partners's AQST Position: Q2 2024 in Review

LMR Partners sold out of Aquestive Therapeutics (AQST) in Q2 2024, closing a stake of 414,480 shares — an estimated $1.77M sold.

LMR Partners first reported a position in AQST in Q2 2021 and held it in 2 quarters. The position peaked at $1.77M in Q1 2024. 97 funds tracked by Wall St. Rank hold AQST as of Q2 2024.

LMR Partners reported no remaining Aquestive Therapeutics position as of Q2 2024 after selling out during the quarter.
LMR Partners sold 414,480 Aquestive Therapeutics shares in Q2 2024, an estimated $1.77M.
LMR Partners first reported a position in Aquestive Therapeutics in Q2 2021 and held it in 2 quarters.
LMR Partners's Aquestive Therapeutics position peaked at $1.77M in Q1 2024.
97 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2024.

Based on LMR Partners's 13F filing for Q2 2024, filed 14 Aug 2024.